CD274 and neoplasm: The overall response rate (ORR) and progression-free survival (PFS) reached promising values, especially in patients with a tumour proportion score (TPS) of PD-L1 expression ≥1% (i.e., more than 1% of tumour cells with PD-L1 expression).